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Abstract
Neuropathic pain is common in peripheral nerve injury and often fails to respond to ordinary
medication. Here, we investigated whether the two novel epigallocatechin-3-gallate
(EGCG) polyphenolic derivatives, compound 23 and 30, reduce the neuropathic pain in
mice chronic constriction nerve injury (CCI). First, we performed a dose-response study to
evaluate nociceptive sensation after administration of EGCG and its derivatives 23 and 30,
using the Hargreaves test at 7 and 21 days after injury (dpi). We daily administered EGCG,
23 and 30 (10 to 100 mg/Kg; i.p.) during the first week post-CCI. None of the doses of com-
pound 23 caused significant pain diminution, whereas 50mg/kg was optimal for both EGCG
and 30 to delay the latency of paw withdrawal. With 50 mg/Kg, we showed that EGCC pre-
vented the thermal hyperalgesia from 7 to 21 dpi and compound 30 from 14 to 56 dpi. To
evaluate the molecular mechanisms underpinning why EGCG and compound 30 differen-
tially prevented the thermal hyperalgesia, we studied several biochemical parameters in the
dorsal horn of the spinal cord at 14 and 56 dpi. We showed that the effect observed with
EGCG and compound 30 was related to the inhibition of fatty acid synthase (FASN), a
known target of these polyphenolic compounds. Additionally, we observed that EGCG and
compound 30 reduced the expression of CCI-mediated inflammatory proteins and the nu-
clear localization of nuclear factor-kappa B at 14 dpi, but not at 56 dpi. We also strongly de-
tected a decrease of synaptic plasma membrane levels of N-methyl-D-asparte receptor 2B
in CCI-mice treated with compound 30 at 56 dpi. Altogether, compound 30 reduced the
chronic thermal hyperalgesia induced by CCI better than the natural compound EGCG.
Thus, our findings provide a rationale for the preclinical development of compound 30 as an
agent to treat neuropathic pain.
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INTRODUCTION
Neuropathic pain is caused by injury or disease to the peripheral or central nervous system
with no available effective treatment. After peripheral nerve injury, the characteristic features
of neuropathic pain are spontaneous pain, hyperalgesia and allodynia [1]. These symptoms are
caused by alteration of signaling pathways in neuronal populations located in the dorsal root
ganglion, the spinal cord and cerebral areas [2]. Within the dorsal horn of the spinal cord,
the activation of the second order sensory neurons contributed to the development and preser-
vation of neuropathic pain [2], through the activation of several mechanisms, such as the pro-
duction of inflammatory cytokines [3], the exacerbate activation of N-methyl-D-aspartate
(NMDA) receptor [4] and the stimulation of transcriptional factors, such as the nuclear factor-
kappa B (NF-κB) cascade [5]. Consequently, the development of new pharmacological agents
with the capacity to interact with these spinal mechanisms could be a therapeutic solution for
the neuropathic pain.
Epigallocatechin-3-gallate (EGCG), the main and most active catechin of green tea, is
known to have therapeutic properties in many systems, included the nervous system. Some ex-
perimental works showed protective effects of EGCG against ischemia [6], neurodegenerative
diseases [7, 8] and spinal cord injury [9–11]. Regarding neuropathic pain, few works have dem-
onstrated an antinociceptive effect of EGCG. Recently, it has been reported in rats that intra-
thecal administration of EGCG attenuates mechanical allodynia and thermal hyperalgesia after
chronic constriction nerve injury [12] and reduces mechanical allodynia after spinal nerve liga-
tion [13]. These beneficial effects have been attributed to the antioxidant activity against nitric
oxide [10, 13, 14] and reduction of pro-inflammatory cytokines expression [10, 12]. Other in-
teresting targets have been described in non-neural cells, such as the enzyme fatty acid synthase
(FASN). FASN catalyzes the synthesis of palmitate providing substrates to affect multiple
cellular functions and it has been proposed as a therapeutic target in cancer [15]. Nevertheless,
there are only few studies reporting the antinociceptive effect of EGCG at phases longer than
two weeks after injury and its mechanism of action remains unclear. For instance, Renno et al
[16] have recently shown that EGCGmodulated chronic injured spinal cord in rats.
The therapeutic effect of EGCG has been well explored in cancer research showing some
limitations for its in vivo effectiveness. EGCG exhibit a poor oral bioavailability, possibly due
to the inability of EGCG to pass through the gut [17]. Furthermore, the EGCG is unstable be-
cause the hydroxyl groups could be modified [18] reducing its biological activity. To resolve
these limitations, new polyphenolic compounds related to EGCG have been developed, show-
ing higher therapeutic activity than EGCG [17, 19–21]. However, the effect of synthetic EGCG
analogues has not been explored in nervous system-related disorders. Here, we compare the ef-
fects of EGCG and two polyphenolic derivatives related to EGCG (compounds 23 and 30) in a
mice model of neuropathic pain induced by chronic constriction injury of sciatic nerve. More-
over, we analyze in the dorsal horn of the spinal cord by which mechanism these polyphenolic
compounds can exert their antinociceptive effect.
MATERIAL ANDMETHODS
Drugs and chemicals
The epigallocatechin-3-gallate (EGCG) was purchased from Sigma-Aldrich (St Louis, MI). The
two synthetic EGCG derivatives: 1,5-Bis [(3,4,5-trihydroxybenzoyl) oxy] naphthalene (com-
pound 23) and 4,40-Bis [(3,4,5-trihydroxybenzoyl) oxy]-1,10-biphenyl (compound 30) were
synthesized as previously described [21]. The Dc protein assay kit was purchased from Bio-
Rad Laboratories (Hercules, CA). The Total RNA isolation nucleo-spin RNA II kit was from
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Macherey-Nagel (Düren, Germany) and the StratraScript First Strand cDNA Synthesis System
was purchased from Stratagene (Santa Clara, CA). The ECWestern Blotting Detection Reagent
was from Santa Cruz Biotechnology (Santa Cruz, CA) and the Hybond-C Extra Nitrocellulose
membranes were purchased from Amersham (Little Chalfont, UK). All other chemicals were
obtained from Sigma-Aldrich. Finally, the 6–0 poly-glycolic acid synthetic absorbable suture
and 5–0 nylon suture were purchased from Suturas Aragó (Barcelona, Spain).
Animals
Female Balb-c mice (21–22 g) were obtained from Charles River Laboratories (France). For the
dose response study of EGCG and compounds 23 and 30, 5 animals per group were used. To
analyze the time-dependent effect of 50 mg/kg of EGCG and the compounds 23 and 30, 15 ani-
mals per group were utilized. Another set of animals were used for the study at 14 days post-
injury (dpi). In each case, 5 animals were utilized to study the fatty acid synthase activity,
5 animals for the PCR assays and 5 animals for the biochemical studies. At 14 and 56 dpi, mice
were sacrificed with sodium pentobarbital (90 mg/kg; i.p.). Mice were housed with access to
food and water ad libitum in a colony room kept at 19–22°C and 40–60% humidity, under a
12:12 hours light/dark cycle. All experimental procedures adhered to the recommendation of
the European Union and the US Department of Health for the care and use of laboratory ani-
mals and were approved by the Ethics Committee of the Generalitat de Catalunya and Univer-
sitat de Barcelona (DARP6308).
Chronic constriction injury
The chronic constriction injury (CCI) followed the procedure described elsewhere [22]. Ani-
mals were anesthetized with sodium pentobarbital (50 mg/kg; i.p.), an incision was made in the
right thigh, and the sciatic nerve was exposed. Two loose ligatures with 1 mm apart were then
made around the nerve using the 6–0 poly-glycolic acid synthetic absorbable sutures. The inci-
sion was closed using 5–0 interrupted nylon sutures. A control group was included with sham
surgery where the right sciatic nerve was exposed but not further manipulated. The animals
did not receive postoperative analgesics in order to preserve the pain associated with CCI and
further to avoid undesirable interactions with EGCG or its derivatives.
Pharmacological administration
For dose response studies, EGCG and the two synthetic EGCG derivatives compound 23 and
compound 30 were administered by intra-peritoneal injection at 10, 30, 50 and 100 mg/Kg
(n = 5 mice/compound/dose), 30 minutes after the CCI. To analyze the time-dependent effect
EGCG and the two synthetic EGCG derivatives compound 23 and compound 30 were admin-
istered by intra-peritoneal injection at 50 mg/Kg (n = 15 mice/compound), 30 minutes after
the CCI. Another set of animals were used to study the effect of 50 mg/kg of EGCG and the
two synthetic EGCG derivatives compound 23 and compound 30 at 14 dpi (n = 15 mice/
compound). In all cases, the administration was daily repeated during the first week. All com-
pounds were dissolved in DMSO/saline solution (1:9; v/v), used as vehicle group.
Thermal hyperalgesia
To measure changes in thermal sensation we used the plantar heat test (Ugo Basile, Italy) as
previously described [23]. Briefly, mice were acclimated 5 days (15 min/day) prior to CCI. At
7, 14, 21, 28, 35, 42, 49 and 56 dpi, mice were enclosed in a clear Plexiglas box. After 15 min,
during which the animals were provided with free exploration to habituate to the apparatus,
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infrared light beam was applied to the plantar surface of the forepaw, and paw withdrawal la-
tency was recorded in seconds. The infrared stimulus application automatically shut off at 30
seconds to avoid tissue damage. Four trials were measured randomly for right forepaw with at
least 2 minutes between each trial.
Fatty acid synthase activity
The fatty acid synthase (FASN) activity was assayed in particle-free supernatants by recording
spectrophotometrically at 37°C (Lambda Bio 20, Perkin Elmer Boston, MA, USA, EUA) and
measuring the decrease of A340 nm due to oxidation of NADPH as previously described [24].
Briefly, mice (n = 5 per group) were sacrificed with sodium pentobarbital (90 mg/kg; i.p.) at 14
and 56 dpi. Spinal cord segments distal to T12 vertebra were quickly removed and snap frozen.
The dorsal horn of the spinal cord tissue was homogenized in lysis buffer (250mM sucrose, 20
mMHEPES pH 7.6, 2 mMMgCl2, 1 mMDTT, 1 mM EDTA, 50 mMNaF, 2 mM phenyl-
methylsulfonyl fluoride (PMSF), 1 μg/μL aprotinin, 1 μg/μL leupeptin, 2 mM sodium orthova-
nadate). Homogenized samples were centrifuged at 3,500 x g for 10 minutes, and then
supernatant was collected and centrifuged at 100,000 x g for 30 minutes to obtain supernatants
particle-free. The protein concentrations were determined using the Dc protein assay kit. A
90 μg amount of protein was used for the reaction. A pre-incubation during 15 minutes at
37°C in 0.2 M of potassium phosphate buffer, pH = 7.0 was kept for temperature equilibration.
Then, samples were added to the reaction mixture (200 mM potassium phosphate buffer, pH
7.0; 1 mM EDTA; 1 mM dithiothreitol, 30 μMAcetyl-CoA and 0.24 mMNADPH) and then
were monitored at 340 nm for 3 minutes to measure background NADPH oxidation. After the
addition of 50 μM of malonyl-CoA, the reaction was assayed for 10 minutes to determine
FASN-dependent oxidation of NADPH. Rates were corrected with the background rate of
NADPH oxidation.
Quantitative (Q)-PCR assays
Total RNA was isolated from dorsal horn of spinal cord segments distal to T12 vertebra of all
groups (n = 5 mice per group) using the Total RNA isolation nucleospin RNA II Kit. Purified
RNA (600 ng) was reverse transcribed using the StrataScript First Strand cDNA Synthesis Sys-
tem. The cDNA synthesis was performed at 42°C for 60 minutes according to the manufactur-
er’s instructions. The cDNA was then analyzed by quantitative RT-PCR using the following
TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA): 18S, HS99999901_s1;
TNF-α, Mm00443258_m1; IL-1β, Mm00434228_m1; IL-6, Mm00446190_m1. The RT-PCR
was performed as previously described [25]. Analysis and quantification was obtained with the
comparative quantification analysis program of the Mx-Pro Q-PCR Analysis software version
3.0 (Strategene).
Protein extraction and subcellular fractionation
Mice (n = 5 per group) were sacrificed with sodium pentobarbital (90 mg/kg; i.p.) at 14 and 56
dpi and spinal cord segments distal to T12 vertebra were quickly removed and frozen. For total
protein extraction, the dorsal horn of the spinal cord was homogenized in modified RIPA buff-
er (50 mM Tris–HCl pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholate, 0.2% SDS, 100 mM
NaCl, 1 mM EDTA, 2 mM PMSF, 1 μg/μL aprotinin, 1 μg/μL leupeptin and 2 mM sodium
orthovanadate).
Subcellular fractionation was obtained by differential centrifugation as described elsewhere
[26]. Briefly, tissue was homogenized in lysis buffer (10 mM Tris-HCl pH 7.5, 1 mM EDTA, 1
mMNa3VO4, 0.25 M sucrose, 2 mM PMSF, 1 μg/μL aprotinin, 1 μg/μL leupeptin, 2 mM
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sodium orthovanadate). The homogenate was centrifuged at 2,000 × g for 10 min at 4°C to sep-
arate the nuclei fraction (P1). The P1 was resuspended in lysis buffer. The resulting supernatant
was centrifuged at 10,000×g for 15 min at 4°C to obtain a crude membrane fraction (P2). The
P2 was resuspended and incubated in the lysis buffer containing 0.5% Triton X-100 for 15 min,
and then centrifuged at 25,000 × g for 20 min to obtain the synaptosomal membrane fraction
(P3). Finally, the P3 was resuspended in lysis buffer and centrifuged on a discontinuous sucrose
gradient (0.8 M, 1 M and 1.2 M) at 150,000×g for 2 h. Synaptic plasma membrane (SPM) was
collected from the 1:1.2 M interface and resuspended in 50 mMHEPES, 2 mM EDTA, 1 mM
PMSF, 10 μg/ml aprotinin, 1 μg/ml leupeptin and 2 mM sodium orthovanadate.
Western blotting
Western blotting was performed as previously described [27]. The following primary antibod-
ies were used: anti-FASN (1:1000, BD Bioscience, San Jose, CA); anti-TNF-α, anti-IL-1β, anti-
IL-6 and anti-NFκB (all 1:500, Santa Cruz Biotechnology, Santa Cruz, CA); anti-phosphoNM-
DAR2B (Tyr1472) (1:2000, Affinity Bioreagents, Golden, CO) and anti-NMDAR2B (1:1000,
Chemicon, Temecula, CA). Loading control was performed by reprobing the membranes with
anti-actin (1:10,000; MP Biochemicals, Aurora, OH), anti-NeuN (1:1,000; Chemicon) or anti-
N-cadherin (1:1000, BD Bioscience). Membranes were incubated with the corresponding
horseradish peroxidase-conjugated antibody (1:2,000; Promega, Madison, WI). Immunoreac-
tive bands were visualized using the Western Blotting Luminol Reagent and quantified by a
computer-assisted densitometer (Gel-Pro Analyzer, version 4, Media Cybernetics).
Statistical analysis
All data are expressed as mean ± SEM. All graphs were created with GraphPad Prism 4 Software
Inc. version 4.02 (San Diego, CA). Different statistical analyses were performed as appropriate,
and indicated in the figure legends. Values of p<0.05 were considered statistically significant.
RESULTS
Administration of EGCG and compound 30 differentially prevent the
neuropathic pain induced by chronic constriction injury
In order to know whether EGCG and the two synthetic derivatives compounds 23 and 30 had
the ability to prevent chronic neuropathic pain, we performed a dose-response study to test
their effect on thermal sensation of forepaws in mice after chronic constriction injury (CCI).
First, we daily intra-peritoneal (i.p.) administrated different doses of EGCG, compound 23 and
30 (10, 30, 50 and 100 mg/Kg) during the first week after CCI and we evaluated the latency to
paw withdrawal to thermal sensation at 7 and 21 dpi. We observed that administration of 50
mg/Kg and 100 mg/kg of EGCG delayed the latency to paw withdrawal at 7 and 21 dpi, with
best capacity at 50 mg/Kg (Table 1).
In contrast, no statistically differences were observed at any dose between the group injected
with vehicle and the groups injected with the compound 23 at 7 and 21 dpi (Table 1). Concern-
ing the compound 30, we detected a time-dependent effect at 50 and 100 mg/Kg. As we shown
in Table 1, the administration of 50 mg/Kg and 100 mg/kg of compound 30 delayed the latency
to paw withdrawal only at 21 dpi, with best effect at 50 mg/Kg. No statistically differences were
observed at 10 and 30 mg/Kg (Table 1). As the best effect observed was 50 mg/Kg, we choose
this concentration to evaluate whether the effect of polyphenolic compounds could be main-
tained at more chronic phases. Thus, with a new set of animals, we weekly assessed the thermal
paw withdrawal latency in CCI-mice treated with 50 mg/Kg of EGCG, compound 23 and
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compound 30 from 7 to 56 dpi. Interestingly, we showed a time-dependent effect of EGCG and
compound 30 in the prevention of neuropathic pain measured by thermal stimuli (Fig 1A and
1C). We observed an increase in paw withdrawal latency in CCI-mice treated with EGCG from
7 to 21 dpi, with a greater effect at 7 dpi (Fig 1A). In the other side, CCI-mice treated with the
Table 1. Administration of EGCG and synthetic derivate compound 30 produce an increase in CCI-mediated thermal paw withdrawal latency in a
dose- and time-dependent manner.
10 mg/Kg 30 mg/Kg 50 mg/Kg 100 mg/Kg
Vehicle 4.38±0.72 7 dpi
EGCG 3.93±0.33 5.01±0.35 13.01±1.02*** 9.38±0.66***
Compound 23 4.07±0.31 4.57±0.29 4.38±0.3 4.41±0.27
Compound 30 3.71±0.39 3.93±0.37 4.31±0.3 4.79±0.44
Vehicle 3.48±0.45 21 dpi
EGCG 3.83±0.23 4.28±0.45 8.58±0.9*** 6.15±0.42***
Compound 23 3.89±0.43 3.77±0.59 3.93±0.24 3.71±0.29
Compound 30 4.11±0.51 4.33±0.57 7.61±0.67*** 6.49±0.53***
The latency to paw withdrawal to a thermal stimulus was recorded in CCI-mice treated with vehicle or different doses (10, 30, 50 and 100 mg/kg; i.p.) of
EGCG, compound 23 and compound 30 at 7 and 21 days post injury (dpi). The results are expressed in seconds and data shown are the mean ± SEM
(n = 5). Data were analyzed by two-way ANOVA with Bonferroni’s post-hoc test.
*** p<0.001 compared to vehicle-treated CCI-mice at any dpi.
doi:10.1371/journal.pone.0123122.t001
Fig 1. Administration of EGCG and compound 30 produce a time-dependent increase in CCI-mediated
thermal paw withdrawal latency. The latency to paw withdrawal to a thermal stimulus was recorded in CCI-
mice treated with vehicle and 50mg/Kg of EGCG (A), compound 23 (B) and compound 30 (C) from 7 to 56
days post injury. The results are expressed in seconds and data shown are the mean ± SEM (n = 15). Data
were analyzed by two-way ANOVA with Bonferroni’s post-hoc test. *** p<0.001 compared to vehicle-treated
CCI-mice.
doi:10.1371/journal.pone.0123122.g001
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compound 30 resulted in an augmentation in the paw withdrawal latency from 14 to 56 dpi,
with a highest effect from 35 to 56 dpi (Fig 1C). Concerning the compound 23, we did not de-
tect differences at any time point analyzed (Fig 1B). Stability studies of EGCG and compounds
23 and 30 showed that half-life of compound 23 in human and mouse serum is 1,4±0,3 and 0,3
±0,1 hours, respectively and regarding compound 30, 1,9±0,2 and 0,4±0,3 hours in human and
mouse serum (S1 Table). EGCG half-life in human and mouse serum is inferior to 0,1 hour. In
serum, compound 23 and compound 30 are in equilibrium with their metabolites, which also
displayed strong FASN activity inhibition (S1 Fig), in particular compound 30 (83% of FASN
activity inhibition in SKBr3 human breast cancer cells). In addition, metabolites showed simi-
lar stability as their parental compounds 23 and 30 (data not shown).
The prevention of CCI induced-neuropathic pain by EGCG and
compound 30 is associated to a reduction of FASN activity in the dorsal
horn of the spinal cord
It has been well reported the role of fatty acids in neuropathic pain after peripheral nerve inju-
ries [28–30]. As it has been described in non-neural cells that EGCG inhibits the fatty acid
synthase activity (FASN) [24], we studied the inhibition of FASN activity in the dorsal horn of
the spinal cord of CCI-mice treated with EGCG and the two polyphenolic synthetic derivatives
(compound 23 and compound 30) at 14 (acute) and 56 (chronic) dpi. At 14 dpi, we observed
that the administration of 50 mg/Kg of EGCG and the compound 30 reduced significantly the
FASN activity to 57±8 and 61±8% of vehicle group (Fig 2A; n = 5). No differences were de-
tected in CCI-mice administrated with the compound 23 (Fig 2A; n = 5). Importantly, the re-
duction of FASN activity at 56 dpi was only observed in CCI-mice treated with the compound
30 (Fig 2A; reduction of 32±9% of vehicle; n = 5). In order to know whether the decrease of
FASN activity could be related to variations in FASN protein levels, we studied by western blot
the protein levels of FASN in the dorsal horn of the spinal cord. EGCG, compound 23 and
Fig 2. EGCG and compound 30 inhibit FASN activity in the spinal cord of CCI-mice. (A) The FASN
activity was analyzed in the dorsal horn of the spinal cord of CCI-mice treated with vehicle, and 50 mg/Kg of
EGCG, compound 23 (c23) and compound 30 (c30) as indicated in materials and methods at 14 and 56 days
post injury (dpi). Data were expressed as a percentage with respect to vehicle-treated CCI-mice and
represent the mean± SEM (n = 5). Data were analyzed by one-way ANOVA with Bonferroni’s post-hoc test.
*p<0.05 and ***p<0.001 compared to vehicle-treated CCI-mice. (B) Protein extracts from the dorsal horn of
the spinal cord of control mice (sham; Sh) and CCI-mice treated with vehicle (V), EGCG, compound 23 (c23)
and compound 30 (c30) at 14 and 56 dpi were subjected to western blot to study the FASN protein levels.
Representative immuno-blots showing no differences in FASN levels between all groups are presented. Actin
levels were used as loading control.
doi:10.1371/journal.pone.0123122.g002
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compound 30 had no effect on FASN protein levels in any group at any age (Fig 2B), indicating
that the decrease of FASN activity was not caused by changes in FASN protein levels.
The administration of EGCG and compound 30 produce an acute
decrease of CCI-mediated inflammatory proteins in the dorsal horn of
the spinal cord
We next investigated whether the administration of polyphenolic compounds reverted the CCI
mediated- expression of cytokines in the dorsal horn of the spinal cord. We explored by
RT-PCR the mRNA expression of three cytokines related to neuropathic pain, tumor necrosis
factor-α (TNF-α), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) at 14 and 56 dpi. As we
show in Fig 3A, EGCG and compound 30 induced an important decrease in the mRNA levels
of three cytokines at 14 dpi (approximately a 3-fold decrease compared to vehicle). In contrast
no differences between vehicle and compound 23 were observed in any cytokine (Fig 3A). Sur-
prisingly, this capacity of EGCG and compound 30 was not observed at 56 dpi (Fig 3A). Only a
slight decrease in mRNA levels of IL-6 was detected in CCI-mice treated with compound 30
compared to CCI-mice with vehicle administration (Fig 3A). To know whether changes in
mRNA levels implied variations in protein levels, we studied by Western blot the protein levels
of TNF-α, IL-1β and IL-6. Accordingly to the mRNA levels, the protein levels of the three cyto-
kines were reduced at 14 dpi in CCI-mice treated with EGCG and compound 30 compared to
vehicle group (Fig 3B). At 56 dpi, no differences were detected between treated groups and ve-
hicle group (Fig 3B).
The expression of cytokines in CCI-mediated neuropathic pain has been associated to acti-
vation of NF-κB [5]. So, we next studied the nuclear protein levels of NF-κB in the dorsal horn
of spinal cord of CCI-mice treated with EGCG and the polyphenolic synthetic derivatives at 14
and 56 dpi. According to the cytokine levels observed in Fig 3, we showed that nuclear NF-κB
levels are reduced only in CCI-mice treated with EGCG and compound 30 at 14 dpi (Fig 4A
and 4B). There are no changes in CCI-mice treated with compound 23 at 14 dpi and in all
treated groups at 56 dpi. All together our results suggest that the acute effect of EGCG and
compound 30 against the neuropathic pain induced by CCI seems to be related to the reduc-
tion of inflammatory proteins in the dorsal horn of the spinal cord.
The administration of compound 30 induce a decrease of synaptic
plasma membrane levels of NMDAR2B in the dorsal horn of the spinal
cord of CCI-mice
It has been involved an enhancement of N-methyl-D-aspartate receptor (NMDAR), through
the expression of NMDAR2B subunit, in the dorsal horn of spinal cord with the induction of
neuropathic pain [4]. To know whether the administration of EGCG or the two polyphenolic
synthetic derivatives had the capacity to prevent the activation of NMDAR, we analyzed the
phosphorylated levels of NMDAR2B subunit in the dorsal horn of spinal cord at 14 and 56 dpi.
At 14 dpi, there were no changes in the phospho-levels of NMDAR2B between vehicle group
and treated groups (Fig 5A). Interestingly, although the treatment with EGCG and compound
23 did not induce variations in the phospho-levels of NMDAR2B at 56 dpi, we detected a spe-
cific decrease of the phosphorylation of NMDAR2B in CCI-mice treated with compound 30
compared to vehicle group (Fig 5A). No significant changes were observed in the total levels of
NMDAR2B in any group (Fig 5A). Variations in the levels of tyrosine phosphorylation of
NMDAR2B could be related to a stable surface expression through palmitoylation [31]. To
know whether the decrease of phospho-NMDAR2B observed in CCI-mice treated with com-
pound 30 was associated with a reduction in the surface membrane expression, we analyzed by
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Western blot the levels of NMDAR2B in a synaptic plasma membrane (SPM) fraction of the
dorsal horn of the spinal cord at 56 dpi. We strongly detected a specific decrease in the protein
levels of NMDAR2B in the SPM of CCI-mice treated with compound 30 (Fig 5B). The admin-
istration of EGCG and compound 23 did not result in changes in NMDAR2B levels in the
SPM fractions (Fig 5B). These results suggest that chronic prevention of CCI-induced
Fig 3. Spinal cord of CCI-mice treated with EGCG and compound 30 at 14 dpi showed decreased
levels of inflammatory cytokines (A) Total RNA of the dorsal horn of spinal cord of control mice (sham; Sh)
and CCI-mice treated with vehicle (VEH) and 50 mg/Kg of EGCG, compound 23 (c23) and compound 30
(c30) was isolated at 14 and 56 days post injury (dpi) as indicated in materials and methods. Quantitative
RT-PCR analysis of TNF-α, IL-1β and IL-6 was performed. Data were expressed as fold change normalized
to 18S and represent the mean± SEM (n = 5). * p<0.05 and *** p<0.001 compared to vehicle-treated CCI-
mice using a one-way ANOVA with Bonferroni’s post-hoc test. (B) Protein extracts from the dorsal horn of the
spinal cord of control mice (sham; Sh) and CCI-mice treated with vehicle (VEH) and 50 mg/Kg of EGCG,
compound 23 (c23) and compound 30 (c30) at 14 and 56 days post injury (dpi) were subjected to western blot
to study the TNF-α, IL-1β and IL-6 protein levels. Data were expressed as a percentage with respect to sham-
mice. Results are the mean± SEM (n = 5) and represent the ratio between each protein and actin levels,
obtained by densitometric analysis of western blot. Data were analyzed by one-way ANOVA with Bonferroni’s
post-hoc test. *** p<0.001 compared to shammice and +++p<0.001 compared to vehicle-treated CCI-mice.
(C) Representative immuno-blots are presented.
doi:10.1371/journal.pone.0123122.g003
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Fig 4. Reduced nuclear levels of NF-κB in the spinal cord CCI-mice administrated with EGCG and
compound 30 at 14 dpi. (A) Nuclear protein extracts from the dorsal horn of the spinal cord of control mice
(sham; Sh) and CCI-mice treated with vehicle (VEH) and 50 mg/Kg of EGCG, compound 23 (c23) and
compound 30 (c30) at 14 and 56 days post injury (dpi) were subjected to western blot to study the NF-κB
protein levels. Data were expressed as a percentage with respect sham-mice. Results are the mean± SEM
(n = 5) and represent the ratio between each NF-κB and NeuN levels, obtained by densitometric analysis of
western blot. Data were analyzed by one-way ANOVA with Bonferroni’s post-hoc test. ***p<0.001
compared to shammice and +++p<0.001 compared to and vehicle-treated CCI-mice. (B) Representative
immuno-blots are presented.
doi:10.1371/journal.pone.0123122.g004
Fig 5. Decreased levels of NMDAR2B in the synaptic plasmamembrane of spinal cord of CCI-mice
treated with compound 30 at 56 dpi. (A) Protein extracts from the dorsal horn of the spinal cord of control
mice (sham; sh) and CCI-mice treated with vehicle (VEH) and 50 mg/Kg of EGCG, compound 23 (c23) and
compound 30 (c30) at 14 and 56 days post injury (dpi) were subjected to western blot to study the phospho-
NMDAR2B and NMDAR2B protein levels. Data were expressed as a percentage with respect to sham-mice.
Results are the mean± SEM (n = 5) and represent the ratio between phospho-NMDAR2B and NMDAR2B
levels, obtained by densitometric analysis of western blot. Data were analyzed by one-way ANOVA with
Bonferroni’s post-hoc test. **p<0.01 and ***p<0.001 compared to shammice and +p<0.05 compared to
vehicle-treated CCI-mice. Representative immuno-blots are presented. (B) The synaptic plasmamembrane
of the dorsal horn of the spinal cord at 56 days post injury (dpi) of all groups was obtained as indicated in
materials and methods and then subjected to Western blot to study the levels of NMDAR2B. Data were
expressed as a percentage with respect to sham-mice. Results are the mean± SEM (n = 5) and represent the
ratio between NMDAR2B and N-cadherin levels, obtained by densitometric analysis of western blot. Data
were analyzed by one-way ANOVA with Bonferroni’s post-hoc test. **p<0.01 compared to shammice and
+p<0.05 compared to vehicle-treated CCI-mice. Representative immuno-blots are presented.
doi:10.1371/journal.pone.0123122.g005
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neuropathic pain by compound 30 is associated to a reduction of NMDAR2B levels in the syn-
aptic fractions of the dorsal horn of the spinal cord.
DISCUSSION
The clinical management to treat neuropathic pain is pharmacological therapy, however nowa-
days there is no effective treatment [32, 33]. Here, we showed that the synthetic polyphenol re-
lated to EGCG, compound 30, was significantly more effective than EGCG in reducing thermal
hyperalgesia in a chronic CCI-mice model. While EGCG reduced the thermal hyperalgesia up
to 21 dpi, compound 30 was able to decrease the nociceptive stimulus to 56 dpi. The antinoci-
ceptive effect of EGCG in neuropathic pain models has been previously described in acute [12,
13] and chronic [16] phases. Here we showed that analgesic capacity of EGCG failed to be effec-
tive at chronic stages. In contrast, we provide data showing that compound 30 had the ability to
extend the antinociceptive effect until chronic phases. EGCG exhibits poor oral bioavailability
due to poor absorption and biotransformation reactions. Numerous alterations to EGCGmole-
cule have been described either to improve the integrity of the native compound or to generate
more stable yet similarly efficacious molecules [16, 17]. Our group and others have produced
the synthesis of new polyphenolic derivatives (compound 23 and compound 30, among others)
related to EGCG as anti-cancer agents, improving the in vivo bioavailability and efficacy of
EGCG [17, 19, 20, 21]. Stability studies in human and mouse serum showed that compound 23
and 30 improved half-life and displayed strongest FASN activity inhibition respect their paren-
tal compound, EGCG. In addition, as we previously published, toxicity studies of compound 23
and compound 30 showed that neither 23 nor 30 caused changes on body weight versus the
control group [19, 21, 24]. Food and fluid intake were similar to controls, and altered behavior
or signs of suffering or distress were not observed in mice treated with 23 and 30 (data not
shown). Hepatic and renal function serummarkers (aspartate transaminase, alanine transami-
nase, alkaline phosphatase, creatinin and urea) and hematological function serummarkers
(% neutrophils, % lymphocytes, % monocytes, % platelet cells % hematocrit and hemoglobin)
showed no significant alteration between control and experimental animals treated with com-
pound 23 at daily doses of 5, 25 or 40 mg/Kg, as we previously reported [21]. Regarding com-
pound 30, no significant alteration in hepatic, renal and hematological function serummarkers
between control and experimental animals treated at daily doses of 50 and 75 mg/Kg were de-
tected (see S2 Table). Furthermore, histological examination of liver, heart, kidney lung and
brain showed no microscopic evidence of drug induces toxicity in compound 23- and 30-
animals when compared with control animals (data not shown). In present study found that
body weight loss was less than 1% in animals treated with polyphenols. This pattern also was ob-
served in control mice (data not shown). Here, we show for the first time the beneficial effect of
an EGCG derivative in neuropathic pain. Different clinical trials in neurodegenerative disorders
has been developed using EGCG thus, we thought that our findings provide a rationale for the
preclinical development of compound 30 as an agent to treat neuropathic pain.
We observed that the effect of EGCG and compound 30 on thermal hyperalgesia is strongly
correlated with the inhibition of FASN activity in the dorsal horn of the spinal cord. These find-
ings suggest that in the nervous system, the therapeutic effect of EGCG and compound 30 is
mediated by the reduction of FASN activity, as we and others previously reported in cancer
models [15, 24]. In addition, the polyphenolic derivative with no action on nociceptive stimulus,
compound 23, was not a potent FASN activity inhibitor. Accordingly, we have previously re-
ported the different % of FASN inhibition of compound 23 and 30 (30% versus 90% respective-
ly) [21]. FASNmainly synthesize the fatty acid palmitate [34]. Palmitate is implicated in the
S-palmitoylation of several proteins altering their activity [35, 36]. Some of them are directly
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related to the generation of neuropathic pain in the dorsal horn of the spinal cord: (i) the activity
and expression of pro-inflammatory enzymes is related to palmitoylation [37–40]; (ii) palmitate
also activates the NF-κB transcription factor and induces the expression of pro-inflammatory
cytokines and chemokines in several cells such as adipocytes [41], and muscle cells [42, 43]; and
(iii) palmitoylation regulates the expression and clustering of NR2A and NR2B subunits of
NMDA receptors [44, 45]. Altogether, FASN seems to be an enzyme with capacity to regulate
several spinal mechanisms related to neuropathic pain and we highlighted FASN as an attractive
therapeutic target to reduce the neuropathic pain.
Our study revealed that the acute analgesic effect (14 dpi) of EGCG and compound 30 is as-
sociated with the reduction of the expression of pro-inflammatory cytokines. However, in
chronic phases (56 dpi) another molecular mechanism is involved in this setting. Accordingly,
we observed the same pattern with the nuclear levels of NF-κB. The synthesis of the pro-
inflammatory cytokines TNF-α, IL-1β and IL-6 is mediated by the nuclear activation of NF-
κB, which may play a pivotal role in neuroinflammation [46]. It has been reported that intra-
thecal injection of antisense oligonucleotides directed to p65 subunit of NF-κB alleviates neu-
ropathic pain after chronic constriction injury of the sciatic nerve [47]. Moreover, the
increased expression of pro-inflammatory cytokines in neuropathic pain is considered the
main cause of hyperalgesia [48]. Our results are in accordance with Kuang et al [12] showing
that EGCG reduced thermal hyperalgesia and mechanical allodynia through the decreasing of
the activity of NF-κB and the reduction of the synthesis of pro-inflammatory cytokines such as
TNF-α and IL-1β. Here, we prove that the capacity of EGCG and compound 30 reduced the
neuroinflammation until at least 14 dpi and then disappeared at chronic stages. Accordingly
there is previous report showing that neuropathic pain was associated with the synthesis of
pro-inflammatory cytokines at early stages but not at later stages [48] suggesting the involve-
ment of other mechanisms into developing neuropathic pain at later stages.
Importantly, we associated the antinociceptive effect of compound 30 at chronic phases
with a reduction of NMDA receptor activity. We detected a specific decrease in the phosphory-
lation of NR2B protein levels in CCI-mice treated with compound 30 at 56 dpi. We showed
that the reduction of phospho-levels of NR2B was associated with a decrease in the protein lev-
els in the synaptic plasma membrane. It is well known the involvement of the NMDA receptor
activation in the dorsal horn of the spinal cord for the preservation of neuropathic pain [4]. In-
terestingly, it has been described that the expression of NR2B is restricted to the dorsal horn of
spinal cord [49], and notably in the lamina II [50]. The increase of this subunit is involved in
long-term plastic changes that occur in spinal cord [50] that favors the sensitization of nocicep-
tive neurons located in the dorsal horn of the spinal cord [51]. The potentiation of this sensory
response enhances the chronic hyperalgesia [2, 52]. The posttranslational palmitoylation of
NR2B subunit regulates localization and activity of NMDA receptor [51]. So, it is tempting to
speculate that prolonged inhibition of FASN by compound 30 diminishes the expression of
NR2B in the synaptic plasma membrane, reducing the chronic sensory response that induce
thermal hyperalgesia.
Taken together, our results showed that compound 30, but not EGCG and compound 23,
prolonged the analgesic effect of EGCG in chronic phases. We associated this effect to the inhi-
bition of the enzyme fatty acid synthase (FASN) by compound 30. Moreover, we showed evi-
dences that the antinociceptive effect of compound 30 was mediated by different molecular
mechanisms in the dorsal horn of the spinal cord. In acute phases, compound 30 displayed
their effect reducing neuroinflammation and in chronic stages the effect was through regulat-
ing NR2B expression in the synaptic plasma membrane. In summary, our findings provide a
rationale for further pre-clinical investigation on the therapeutic regimen based on FASN in-
hibitors in neuropathic pain refractory to current therapies.
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